All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On 21 November 2018, Ingrid Glimelius from Uppsala University, Uppsala, SE, and colleagues, published in Blood a retrospective study from the Swedish Lymphoma Registry evaluating the prognostic value of certain comorbidities in mantle cell lymphoma (MCL).
MCL patients presenting with comorbidities, and especially elderly patients, have poor disease prognosis and tolerability towards intensive regimens. The aim of this population-based analysis was to identify the most common comorbidities in MCL patients and to evaluate their effect on treatment choice. The primary endpoints of the study were lymphoma-specific and overall survival (OS), as well as reasons for mortality in MCL patients.
The results of this analysis indicated that almost 50% of the MCL patients in Sweden during the time of the study, presented with a comorbidity at diagnosis. The presence of two or more comorbidities was an independent prognostic factor of worse OS and lymphoma-specific survival. The investigators stated since lymphoma was the main cause of death in male MCL patients irrespective of CCI, there is a clear need for the development of efficient treatments, which should consider the effect of comorbidities like coronary heart disease, connective tissue disease, and renal disorders.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?